Switch to:
More From Other Websites
7:19 am Gilead Sciences announces that the CHMP of the EMA has adopted a positive opinion on Type II... Jul 23 2016
5 Big Drugmakers Reporting Earnings Next Week Jul 22 2016
Options Insight: How to Play Gilead Sciences Jul 22 2016
Options Insight: How to Play Gilead Sciences Jul 22 2016
Gilead Has a Problem. These Three Biotechs Could Be the Solution Jul 22 2016
GILD Developing Next Generation HCV Drugs to Remain Competitive Jul 22 2016
Political Headwinds Dampen Gilead Sciences Outlook Jul 22 2016
These 4 Stocks Could See Negative Catalysts From Earnings -- but What Do the Charts Say? Jul 22 2016
Gilead Gets European CHMP's Positive Opinion On Its Type II Variation Application For Truvada Jul 22 2016
New York-Based Selz Capital’s Top Picks for Q3; High-Yielding Macquarie Infrastructure Corp (MIC)... Jul 22 2016
Gilead Sciences (GILD) Stock Drops Ahead of Q2 Earnings Report Jul 22 2016
Medical Stocks Reporting Early Next Week: GILD, LLY & More Jul 22 2016
European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for... Jul 22 2016
European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for... Jul 22 2016
Downtrend in GILD’s Hepatitis C Drug Affecting Overall Revenues Jul 21 2016
Gilead Earnings on Tap: Can Hepatitis-C Recover? (GILD) Jul 21 2016
Gilead (GILD) Stock Likely to Beat This Earnings Season Jul 21 2016
Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week... Jul 21 2016
Rallying biotech looks ‘interesting’ for value investors, says top-rated analyst Jul 21 2016


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK